

July 28, 2026

Moving towards a balanced model amid volatility...

About the stock Rallis India is a leading agrochemical company with a presence across agriculture input value chain and a strong, healthy pipeline of sustainable products. The offering includes domestic crop care, exports crop care, custom synthesis, soil and plant health and seeds.

- The company has a strong domestic channel network of more than 6,700 dealers and 95,000 retailers besides presence in +30 countries for exports.
- In Q1FY27, Crop care accounted for 68% of overall revenues while the Seeds business accounted for 32% of the revenues.

Result Performance and Investment Rationale:

- Rallis India Q1FY27: Decent print despite high base:** Revenues stood at ₹1,022 crore, up 7% YoY. Segment wise, Crop care (68% of the revenues) reported an uptick of 7% YoY to ₹697 crore. Seeds (32% of revenue) reported an uptick of 7% YoY to ₹325 crore. GPM for the quarter stood at 37.7%, up ~140 bps YoY. EBITDA for the quarter stood at ₹185 crore, up 23% YoY, translating to margins of 18.1%, up ~240 bps YoY. The growth was primarily driven by better volume growth in Crop care and optimisation of fixed costs. EBITDA for the Crop care business came in at ₹86 crore, up ~23% YoY and ₹99 crore for the Seeds business, up ~24% YoY. PAT for the quarter stood at ₹125 crore, up 32% YoY.
- Commendable numbers under adverse circumstances:** Despite strong headwinds such as war situation, delayed monsoon and Kharif sowings, severe heatwave impacting labour productivity among others, the company delivered a decent performance supported by growth in both its Crop care and Seeds businesses. Also note that the Q1FY26 base was exceptionally high, with early monsoon onset and sowing. Crop care growth was primarily driven by a strong 19% increase in the domestic B2C segment and three new launches (2 herbicides and one pesticide). On the other hand, Seeds business growth was driven by nine new launches across Cotton, Paddy, and Millet crops, including two new Cotton hybrids for North India and an Herbicide Tolerant Direct Seed Rice product under the Dhaanya brand. B2B exports were down 16% YoY due to challenging global environment, but on the bright side, the CSM business witnessed balanced performance with volume uptick in select products, offsetting volume shortfall in few other products.
- Long term aspirational target depends on product focus and execution:** While in the near term, current stock liquidation and sowing pattern remains to be key monitorable, the management has maintained its aspirational double-digit revenues growth and ~15% EBITDA margins targets. Strong traction in Seeds and Soil & Plant Health, along with improving contribution from CSM and exports is expected to strengthen growth visibility. The company may continue to witness quarterly gyrations due the vagaries of monsoon but focus on new launches and performance resilience is likely to strengthen the yearly numbers. The company offers a reasonable risk-reward proposition at the current level.


Rating and Target Price: Our Target Price is ₹265 based on 10x EV/EBITDA of ₹437.2 crore

**Particulars**

Particular	₹ crore
Market Capitalization	4,365
Total Debt (FY26)	61
Cash & Invests (FY26)	548
EV	3,878
52-week H/L (₹)	386/216
Equity capital (₹)	19
Face value (₹)	1

Shareholding pattern

	Sep-25	Dec-25	Mar-26	Jun-26
Promoter	55.1	55.1	55.1	55.1
FII	14.2	12.1	11.5	9.1
DII	11.2	11.3	11.3	11.7
Other	19.1	21.2	21.6	23.7

Price Chart**Key risks**

- Adverse and unpredictable weather patterns
- Pricing pressure and de-stocking risk in the exports

Research Analyst

Siddhant Khandekar
siddhant.khandekar@icicisecurities.com

Shubh Mehta
shubh.mehta@icicisecurities.com

Deep Thosani
deep.thosani@icicisecurities.com

Key Financial Summary

Key Financials (₹ crore)	FY24	FY25	FY26	2-year CAGR (FY24-26)	FY27E	FY28E	2-year CAGR (FY26-28E)
Net Sales	2,648.0	2,663.0	2,897.0	4.6%	3,172.1	3,473.7	9.5%
EBITDA	311.0	286.0	361.0	7.7%	399.2	437.2	10.1%
EBITDA Margins (%)	11.7%	10.7%	12.5%		12.6%	12.6%	
Adj. PAT	147.2	124.3	203.1	17.5%	234.7	260.0	13.1%
Adj. EPS (₹)	7.6	6.4	10.7		12.4	13.7	
EV/EBITDA	13.6x	14.0x	10.5x		9.4x	8.3x	
P/E	29.6x	35.0x	23.2x		18.2x	16.4x	
RoE (%)	8.0	6.5	9.9		10.6	10.7	
RoCE (%)	10.9	10.1	13.6		14.2	14.3	

Source: Company, ICICI Direct Research

Q1FY27 Earnings Conference Call Highlights

Crop care Business-

- Domestic Crop Care delivered 19% YoY growth, driven by 15% volume growth, supported by aggressive market execution, higher channel engagement and new product introductions.
- Four new crop care products were launched during the quarter (two herbicides, one insecticide and one soil & plant health product), strengthening the product portfolio.
- Management indicated that future growth will primarily be volume-led, with limited scope for additional price hikes during the season.
- Herbicides emerged as the largest contributor in Q1FY27 and grew 12%.

Exports & CSM-

- Export business remained weak due to subdued demand in Europe, aggressive Chinese pricing and logistics disruptions, particularly impacting Pendimethalin, Acephate and Hexaconazole.
- Management highlighted that CSM remains relatively insulated owing to contractual arrangements, with shipments to a new US customer commencing during the quarter. The company is working on 3–4 additional CSM projects and plans to launch 3–4 catalogue products over the next three years, although scaling remains gradual.

Seeds Business-

- Seeds revenue grew 6% YoY, driven primarily by pricing, while cotton volumes remained under pressure due to lower acreage and proliferation of illegal HTBT cotton.
- Management expects cotton to remain subdued in FY27, with growth increasingly driven by rice, maize, millet and mustard, where the company has launched several new products.
- Seed inventory remains comfortable, with industry carrying surplus inventory in most crops except potential uncertainty around future cotton production depending on rainfall during October–November.

Herbicides-

- During Q1 FY27, herbicides emerged as the largest contributor within the crop protection portfolio and registered ~12% growth.
- Management believes the increasing adoption of Direct Seeded Rice (DSR) in North India represents a structural opportunity, as DSR cultivation requires significantly higher herbicide usage than conventional transplanted rice.
- The company has launched new rice herbicides and has also begun participating in herbicide-tolerant DSR technology through licensing partnerships.

Margins & Strategy

- Q1FY27 growth was supported by a combination of ~5–6% pricing and modest volume growth.
- Management indicated that most price hikes have already been implemented, with limited scope for further mid-season increases.
- Going forward, the focus will be on volume growth, competitiveness and market-share gains. Raw material prices have moderated from peak levels, although fresh Rabi procurement from August could see renewed pressure if geopolitical tensions persist.
- Management expects product mix and cost optimisation to support its long-term ambition of delivering 15%+ EBITDA margins consistently.

Working Capital & Channel Inventory:

- Net working capital increased by around 15–20 days YoY as farmer liquidity was diverted towards fertiliser purchases.
- However, channel inventory has largely normalised. Management remains cautious on sales returns given uncertainty around crop progression and liquidation and will adopt conservative provisioning.
- Returns are expected to remain crop- and product-specific, particularly for pre-emergence herbicides in soybean, rice and groundnut.


Demand & Monsoon

- Management highlighted a challenging Q1FY27 environment due to delayed monsoon, weak Kharif sowing, heatwave conditions, lower cotton acreage and channel liquidity pressure as distributors prioritised fertiliser stocking.
- Management expects the domestic agrochemical industry to grow 6–8% in FY27, while seed industry growth is expected at mid-to-high single digits, excluding the weak cotton segment.

Management Outlook

- While cotton remains a near-term headwind, management expects rice, maize, millet, chilli and biologicals to offset weakness and support domestic growth. Chilli demand is expected to recover meaningfully in Q2–Q3, aided by improved crop economics.

Exhibit 1: 2 year forward EV/EBITDA band



Source: Company, ICICI Direct Research

Financial summary

Exhibit 2: Profit and loss statement

₹ crore

Year end March	FY25	FY26	FY27E	FY28E
Total Operating Income	2,663.0	2,897.0	3,172.1	3,473.7
Growth (%)	0.6	8.8	9.5	9.5
Raw Material Expenses	1,581.0	1,727.0	1,903.3	2,084.2
Gross Profit	1,082.0	1,170.0	1,268.9	1,389.5
Employee Cost	275.0	283.0	333.1	364.7
Other Operating Expenses	521.0	526.0	536.6	587.5
EBITDA	286.0	361.0	399.2	437.2
Growth (%)	-8.0	26.2	10.6	9.5
Other Income	32.0	42.0	42.0	42.0
EBITDA, including OI	318.0	403.0	441.2	479.2
Depreciation	120.0	117.0	120.0	125.9
Net Interest Exp.	12.0	10.0	8.2	6.6
Other exceptional items	1.0	-26.0	0.0	0.0
PBT	187.0	250.0	313.0	346.7
Total Tax	62.0	66.0	78.2	86.7
Tax Rate	33.2%	26.4%	25.0%	25.0%
PAT	125.0	184.0	234.7	260.0
Adj.PAT after Minority interest	124.3	203.1	234.7	260.0
Adj. EPS (₹)	6.4	10.7	12.4	13.7
Shares Outstanding	19.5	19.0	19.0	19.0

Source: Company, ICICI Direct Research

Exhibit 3: Cash flow statement

₹ crore

Year end March	FY25	FY26	FY27E	FY28E
PBT & Extraordinary	187.0	250.0	313.0	346.7
Depreciation	120.0	117.0	120.0	125.9
After other adjustments				
(Inc) / Dec in Working Capital	72.0	-121.0	-169.3	-166.4
Taxes	-55.0	-68.0	-78.2	-86.7
Others	-29.0	-6.0	8.2	6.6
CF from operating activities	295.0	172.0	193.6	226.1
Purchase of Fixed Assets	-74.0	-45.0	-74.0	-75.0
Others	-140.0	-50.0	0.0	0.0
CF from investing activities	-214.0	-95.0	-74.0	-75.0
Proceeds from issue of shares	0.0	0.0	0.0	0.0
Borrowings (Net)	0.0	7.0	-20.0	0.0
Others	-80.0	-73.0	-65.2	-63.6
CF from financing activities	-80.0	-66.0	-85.2	-63.6
Net cash flow	1.0	11.0	34.4	87.5
Effects of foreign currency translation	0.0	0.0	0.0	0.0
Opening Cash	32.0	31.0	46.0	80.4
Closing Cash	31.0	46.0	80.4	167.9

Source: Company, ICICI Direct Research

Exhibit 4: Balance sheet

₹ crore

Year end March	FY25	FY26	FY27E	FY28E
Liabilities				
Share Capital	19.5	19.0	19.0	19.0
Reserves	1,884.6	2,024.0	2,201.7	2,404.7
Total Shareholders' Funds	1,904.0	2,043.0	2,220.7	2,423.7
Minority Interest	0.0	0.0	0.0	0.0
Long Term Borrowings	51.0	45.0	25.0	25.0
Net Deferred Tax liability	9.0	14.0	14.0	14.0
Other long-term liabilities	1.0	1.0	10.6	11.7
Long term provisions	44.0	32.0	32.1	35.1
Current Liabilities and Provisions				
Short term borrowings	12.0	16.0	16.0	16.0
Trade Payables	541.0	728.0	956.0	1,046.9
Other Current Liabilities	400.0	413.0	296.0	324.1
Short Term Provisions	12.0	53.0	7.9	8.7
Total Current Liabilities	965.0	1,210.0	1,275.9	1,395.7
Total Liabilities	2,974.0	3,345.0	3,578.4	3,905.2
Assets				
Net Block	708.0	654.0	609.0	558.1
Capital Work in Progress	25.0	11.0	10.0	10.0
Intangible assets under devl.	27.0	21.0	21.0	21.0
Goodwill on Consolidation	196.0	196.0	196.0	196.0
Non-current investments	4.0	4.0	4.0	4.0
Deferred tax assets	98.0	104.0	104.0	104.0
Long term loans and advances	16.0	11.0	13.2	14.4
Other Non-Current Assets	35.0	35.0	207.2	226.9
Current Assets, Loans & Advances				
Current Investments	408.0	502.0	502.0	502.0
Inventories	751.0	959.0	1,129.8	1,332.4
Sundry Debtors	541.0	616.0	608.4	666.2
Cash and Bank	31.0	46.0	80.4	167.9
Loans and Advances	0.0	0.0	0.0	0.0
Other Current assets	134.0	186.0	93.4	102.3
Current Assets	1,865.0	2,309.0	2,414.0	2,770.8
Total Assets	2,974.0	3,345.0	3,578.4	3,905.2

Source: Company, ICICI Direct Research

Exhibit 5: Key ratios

Year end March	FY25	FY26	FY27E	FY28E
Per share data (₹)				
Adj. EPS	6.4	9.7	12.4	13.7
Adj. Cash EPS	12.6	15.8	18.7	20.3
BV	97.9	107.5	116.9	127.6
DPS	3.0	3.0	3.0	3.0
Operating Ratios (%)				
Gross Margin (%)	40.6	40.4	40.0	40.0
EBITDA Margin (%)	10.7	12.5	12.6	12.6
PAT Margin (%)	4.7	7.0	7.4	7.5
Debtor Days	60	60	70	70
Inventory Days	120	120	130	140
Creditor Days	120	120	110	110
Cash Conversion Cycle	60	60	90	100
Return Ratios (%)				
Return on Assets (%)	4.2	6.1	6.6	6.7
RoCE (%)	10.1	13.6	14.2	14.3
Core RoIC (%)	10.9	15.7	16.6	17.3
RoE (%)	6.5	9.9	10.6	10.7
Solvency Ratios				
Total Debt / Equity	0.0	0.0	0.0	0.0
Interest Coverage	16.5	28.6	39.1	53.4
Current Ratio	1.9	1.9	1.9	2.0
Quick Ratio	1.2	1.1	1.0	1.0
Asset Turnover	1.9	2.0	2.1	2.1
Valuation Ratios (x)				
EV/EBITDA	14.0	10.5	9.4	8.3
P/E	35.0	23.2	18.2	16.4
P/B	2.3	2.1	1.9	1.8
EV/Sales	1.5	1.3	1.2	1.0

Source: Company, ICICI Direct Research

RATING RATIONALE

ICICI Direct endeavours to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%

Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research
Desk,
ICICI Securities Limited,
Third Floor, Brillanto
House,
Road No 13, MIDC,
Andheri (East)
Mumbai – 400 093
research@icicidirect.com

ANALYST CERTIFICATION

I/We, Siddhant Khandekar, Inter CA; Shubh Mehta, MBA (Tech); Deep Thosani, MBA; Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock broking and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number –INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Jeetu Jawrani Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report